Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re Preference Shares

14 Jan 2005 07:00

Medisys PLC14 January 2005 For immediate release 14 January 2005 Medisys PLC ("Medisys" or the "Company") Re-purchase and cancellation of A and C Preference Shares in Hypoguard Holding Co. Limited ("HOLDCO") Medisys announces that the 13 million redeemable A preference shares in HOLDCO(the "A Preference Shares"), and the 4 million redeemable C preferenceshares in HOLDCO (the "C Preference Shares"), both subscribed for in 1999as part of the Joint Venture with Elan Corporation plc ("Elan") are to bere-purchased by HOLDCO and cancelled. HOLDCO is a wholly owned subsidiary of theCompany incorporated in Bermuda. The re-purchase will be satisfied by the issue of an aggregate of 30,804,706 newordinary shares of 1 pence each in the Company (the "New Ordinary Shares")to Kings Road Investments Ltd, a company not connected to Elan, which hasacquired the rights to the New Ordinary Shares. Admission of the New Ordinary Shares to listing on the Official List of the UKListing Authority and to trading on the London Stock Exchange is expected totake place on 19 January 2005 whereupon the re-purchase of the A PreferenceShares and the C Preference Shares will be completed. Kings Road Investments Ltd has agreed to a six months orderly market stagedlock-up restriction in respect of market disposals of the New Ordinary Shares. Background In 1999, Medisys announced that it had entered into a joint venture with Elan,the Irish speciality pharmaceutical group and certain affiliated companies, forthe development of biosensor-based blood glucose diagnostic products. Inaddition, the Joint Venture acquired the rights to certain technologies relatingto the in-vivo monitoring of blood glucose in diabetics from Marathon MedicalTechnologies, Inc. ("Marathon"), a joint venture company owned by BioJectMedical Technologies, Inc. and Elan. Under the terms of the Joint Venture, Hypoguard Limited (a wholly ownedsubsidiary of Medisys) and Elan each provided a worldwide exclusive licence tocertain technologies to Hypoguard Development Co Limited ("JVCO"), a newlyincorporated wholly owned subsidiary of Medisys. In addition, Hypoguard licensedto JVCO its Arrow technology and Elan granted a licence to JVCO of an enablingpump technology. JVCO acquired from Marathon certain patent and intellectualproperty rights licensed from the Elan Group relating to technologies used inin-vivo monitoring of blood glucose in diabetics. In order to enable JVCO to fund the licence and assignment fees and thedevelopment of the technologies, certain funding was provided by Elan. Elan International Services Ltd. ("EIS") subscribed for 13 millionredeemable A preference shares in HOLDCO for a total subscription price of US$13million. The A Preference Shares were subsequently sold by EIS to ElanPharmaceutical Investments III, Ltd. ("EPIL III"), a wholly ownedsubsidiary of EIS. The shares are generally redeemable at par plus a premium of5% per annum at any time between the second and ninth anniversaries of theirissue, although Medisys has the right to apply the proceeds of redemptiontowards the issue to the holder of new Medisys Ordinary Shares at a price ofUS$0.7505 per share. The holder also had the right to require that the proceeds of redemption beapplied towards the purchase by the holder from HOLDCO of 50% of the issuedshare capital of JVCO (the "JVCO Share Exchange Right") save that Medisyscould, at its option, deny this right by (a) the issue to the holder of newMedisys Ordinary Shares at a price of US$0.4938 per share and (b) the payment tothe holder of a royalty based on market sales of products developed by JVCO. TheJVCO Share Exchange Right was effectively cancelled as part of the joint venturetermination arrangements announced by the Company on 2 December 2004. EIS subscribed for 5 million redeemable B preference shares in HOLDCO for atotal subscription price of US$5 million. The shares were generally redeemableby the holder at par plus a premium of 6% per annum at any time between thesecond and ninth anniversaries of their issue, although Medisys had the right toapply the proceeds of redemption towards the issue to the holder of new MedisysOrdinary Shares at a price of US$0.6518 per share provided the market price ofMedisys Ordinary Shares was greater than US$0.6518. In the event that the marketprice of Medisys Ordinary Shares was less than US$0.6518, then the market priceof Medisys Ordinary Shares would become the conversion price and the applicableredemption premium increased on a scale from 6% to a maximum of 15% per annum.The maximum applicable redemption premium was reached when the market price forMedisys Ordinary Shares was US$.4120 per share. The Company announced, as partof the joint venture termination arrangements, the purchase and cancellation ofthe redeemable B preference shares on 2 December 2004, the consideration forwhich was satisfied by the issue of 17 million new ordinary shares of 1 pence inthe Company to EIS and the payment of £560,000 in cash. The cash element of theconsideration is to be paid in eight equal quarterly instalments of £70,000, thefirst of which was paid on 31 December 2004 and the last of which is due andpayable on 30 September 2006. EIS also subscribed for 4 million redeemable C preference shares in HOLDCO for atotal subscription price of US$4 million. The C preference shares weresubsequently sold by EIS to EPIL III. The shares are generally redeemable by theholder at par plus a premium of 15% per annum at any time between the second andninth anniversaries of their issue, although Medisys has the right to apply theproceeds of redemption towards the issue to the holder of 8,101,266 new MedisysOrdinary Shares. - Ends -Enquiries: Medisys PLC 020 7563 5200Michael Barry, Chief Financial Officer Weber Shandwick Square Mile 020 7067 0700Kevin Smith/Sarah MacLeod This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Dec 20185:38 pmRNSTransaction in Own Shares
10th Dec 20186:03 pmRNSTransaction in Own Shares
7th Dec 20186:03 pmRNSTransaction in Own Shares
6th Dec 20185:52 pmRNSTransaction in Own Shares
6th Dec 20187:00 amRNSUbima Appraisal Update
5th Dec 20185:37 pmRNSTransaction in Own Shares
4th Dec 20185:35 pmRNSTransaction in Own Shares
3rd Dec 20186:02 pmRNSTransaction in Own Shares
3rd Dec 20187:00 amRNSTransaction in Own Shares
29th Nov 20186:06 pmRNSRefinancing of Reserve-Based Lending Facility
29th Nov 20186:01 pmRNSTransaction in Own Shares
28th Nov 20186:08 pmRNSTransaction in Own Shares
27th Nov 20185:28 pmRNSTransaction in Own Shares
26th Nov 20185:30 pmRNSTransaction in Own Shares
23rd Nov 20186:08 pmRNSTransaction in Own Shares
22nd Nov 20186:18 pmRNSTransaction in Own Shares
21st Nov 20185:30 pmRNSTransaction in Own Shares
21st Nov 20187:00 amRNSDirector and PCA Dealing
21st Nov 20187:00 amRNSTransaction in Own Shares
19th Nov 20187:00 amRNSShare Buyback Programme
16th Nov 20187:00 amRNSGbetiokun Operations Update
15th Nov 20187:01 amRNSChange of Joint Broker
15th Nov 20187:00 amRNSChange of Nominated Advisor and Joint Broker
12th Nov 20187:00 amRNSConfirmation of Licence Renewal
29th Oct 201810:35 amRNSDirector and PCA Dealing
26th Oct 20187:00 amRNSOperations Update
5th Oct 201811:45 amRNSHolding(s) in Company
20th Sep 20187:00 amRNSInterim Results for the six months to 30 June 2018
18th Sep 20187:00 amRNSOpuama and Ubima Update
16th Aug 20187:00 amRNSOpuama Operations Update
31st Jul 20187:00 amRNSCommencement of Ubima Appraisal
25th Jul 20187:00 amRNSOpuama-10 Update
9th Jul 20181:08 pmRNSDirector and PCA Dealing
6th Jul 201811:58 amRNSDirector and PCA Dealing
4th Jul 20187:00 amRNSOpuama Field Operations Update
3rd Jul 201811:41 amRNSDirector and PCA Dealing
2nd Jul 20185:51 pmRNSHolding(s) in Company
2nd Jul 20182:22 pmRNSDirector and PCA Dealing
26th Jun 201812:56 pmRNSDirector and PCA Dealing
21st Jun 20184:49 pmRNSDirector and PCA Dealing
20th Jun 20184:04 pmRNSAppointment of Non-Executive Director
14th Jun 20187:00 amRNSOpuama-9 Update
25th May 20189:15 amRNSLong Term Incentive Plan ("LTIP") Awards
17th May 20181:00 pmRNSCapital Markets Day Presentation
17th May 201812:09 pmRNSRig contract signed for the drilling of Ubima-1
16th May 20187:00 amRNSOpuama-9 Update
15th May 20185:33 pmRNSResult of Annual General Meeting
23rd Apr 20189:30 amRNSPosting of Annual Report & Notice of AGM
18th Apr 20187:00 amRNSFinal Results for the Year ended 31 December 2017
18th Apr 20187:00 amRNSOpuama-9 Operations Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.